Most uveitis-related vision loss is the result of chronic inflammation of the posterior segment of the eye. Although noninfectious anterior uveitis is typically treated successfully with topical corticosteroids, noninfectious uveitis of the posterior segment (NIU-PS) can be more difficult to manage, as it is generally not responsive to topical medication. Corticosteroids remain the clinical mainstay for this subset of patients, but the use of other immunomodulators, such as tumor necrosis factor (TNF)-alpha inhibitors, has become increasingly widespread. This claims data analysis gives manufacturers of current therapies, as well as those developing novel agents, real-world insights regarding recent trends in the treatment of NIU-PS.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Ocular Therapeutix, Bausch + Lomb, AbbVie
Key drugs: Humira, Durezol, Ozurdex
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more-detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.